Ubiquitin-specific proteases (USPs) in leukemia: a systematic review.
Deubiquitinase enzymes
Leukemia
Ubiquitin proteasome system
Ubiquitin-specific proteases
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
20
04
2024
accepted:
09
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
Leukemia, a type of blood cell cancer, is categorized by the type of white blood cells affected (lymphocytes or myeloid cells) and disease progression (acute or chronic). In 2020, it ranked 15th among the most diagnosed cancers and 11th in cancer-related deaths globally, with 474,519 new cases and 311,594 deaths (GLOBOCAN2020). Research into leukemia's development mechanisms may lead to new treatments. Ubiquitin-specific proteases (USPs), a family of deubiquitinating enzymes, play critical roles in various biological processes, with both tumor-suppressive and oncogenic functions, though a comprehensive understanding is still needed. This systematic review aimed to provide a comprehensive review of how Ubiquitin-specific proteases are involved in pathogenesis of different types of leukemia. We systematically searched the MEDLINE (via PubMed), Scopus, and Web of Science databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) to identify relevant studies focusing on the role of USPs in leukemia. Data from selected articles were extracted, synthesized, and organized to present a coherent overview of the subject matter. The review highlights the crucial roles of USPs in chromosomal aberrations, cell proliferation, differentiation, apoptosis, cell cycle regulation, DNA repair, and drug resistance. USP activity significantly impacts leukemia progression, inhibition, and chemotherapy sensitivity, suggesting personalized diagnostic and therapeutic approaches. Ubiquitin-specific proteases also regulate gene expression, protein stability, complex formation, histone deubiquitination, and protein repositioning in specific leukemia cell types. The diagnostic, prognostic, and therapeutic implications associated with ubiquitin-specific proteases (USPs) hold significant promise and the potential to transform leukemia management, ultimately improving patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Leukemia, a type of blood cell cancer, is categorized by the type of white blood cells affected (lymphocytes or myeloid cells) and disease progression (acute or chronic). In 2020, it ranked 15th among the most diagnosed cancers and 11th in cancer-related deaths globally, with 474,519 new cases and 311,594 deaths (GLOBOCAN2020). Research into leukemia's development mechanisms may lead to new treatments. Ubiquitin-specific proteases (USPs), a family of deubiquitinating enzymes, play critical roles in various biological processes, with both tumor-suppressive and oncogenic functions, though a comprehensive understanding is still needed.
AIM
OBJECTIVE
This systematic review aimed to provide a comprehensive review of how Ubiquitin-specific proteases are involved in pathogenesis of different types of leukemia.
METHODS
METHODS
We systematically searched the MEDLINE (via PubMed), Scopus, and Web of Science databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) to identify relevant studies focusing on the role of USPs in leukemia. Data from selected articles were extracted, synthesized, and organized to present a coherent overview of the subject matter.
RESULTS
RESULTS
The review highlights the crucial roles of USPs in chromosomal aberrations, cell proliferation, differentiation, apoptosis, cell cycle regulation, DNA repair, and drug resistance. USP activity significantly impacts leukemia progression, inhibition, and chemotherapy sensitivity, suggesting personalized diagnostic and therapeutic approaches. Ubiquitin-specific proteases also regulate gene expression, protein stability, complex formation, histone deubiquitination, and protein repositioning in specific leukemia cell types.
CONCLUSION
CONCLUSIONS
The diagnostic, prognostic, and therapeutic implications associated with ubiquitin-specific proteases (USPs) hold significant promise and the potential to transform leukemia management, ultimately improving patient outcomes.
Identifiants
pubmed: 39048945
doi: 10.1186/s12885-024-12614-x
pii: 10.1186/s12885-024-12614-x
doi:
Substances chimiques
Ubiquitin-Specific Proteases
EC 3.4.19.12
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
894Informations de copyright
© 2024. The Author(s).
Références
Chennamadhavuni A, Lyengar V, Shimanovsky A. Continuing Education Activity.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood J Am Soc Hematol. 2016;127(20):2391–405.
Kibler CE, Chabot-Richards DS. Molecular Pathology of Leukemia. Molecular Surgical Pathology: Springer; 2023. pp. 681–709.
Di Costanzo A, Del Gaudio N, Conte L, Altucci L. The ubiquitin proteasome system in hematological malignancies: new insight into its functional role and therapeutic options. Cancers. 2020;12(7):1898.
pubmed: 32674429
pmcid: 7409207
Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6(5):369–81.
pubmed: 16633365
Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8(6):438–49.
pubmed: 18500245
pmcid: 2711846
Dharadhar S, Kim RQ, Uckelmann M, Sixma TK. Quantitative analysis of USP activity in vitro. Methods in Enzymology. 618: Elsevier; 2019. pp. 281–319.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
pubmed: 25554246
pmcid: 4320440
Paulsson K, Bekassy A, Olofsson T, Mitelman F, Johansson B, Panagopoulos I. A novel and cytogenetically cryptic t (7; 21)(p22; q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42. Leukemia. 2006;20(2):224–9.
pubmed: 16357831
Foster N, Paulsson K, Sales M, Cunningham J, Groves M, O’Connor N, et al. Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t (7; 21) in myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol. 2010;148(6):938–43.
pubmed: 20064152
Giguere A, Hébert J. Microhomologies and topoisomerase II consensus sequences identified near the breakpoint junctions of the recurrent t (7; 21)(p22; q22) translocation in acute myeloid leukemia. Genes Chromosom Cancer. 2011;50(4):228–38.
pubmed: 21319259
Paulraj P, Diamond S, Razzaqi F, Ozeran JD, Longhurst M, Andersen EF, et al. Pediatric acute myeloid leukemia with t (7; 21)(p22; q22). Genes Chromosom Cancer. 2019;58(8):551–7.
pubmed: 30706625
Schwer H, Liu L-Q, Zhou L, Little M-T, Pan Z, Hetherington CJ, et al. Cloning and characterization of a novel human ubiquitin-specific protease, a homologue of murine UBP43 (Usp18). Genomics. 2000;65(1):44–52.
pubmed: 10777664
Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, et al. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU. 1-dependent mechanism. Blood J Am Soc Hematol. 2018;132(4):423–34.
Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017;13(12):1207–15.
pubmed: 28967922
pmcid: 6314479
Cartel M, Mouchel P-L, Gotanègre M, David L, Bertoli S, Mansat-De Mas V, et al. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy. Leukemia. 2021;35(2):417–32.
pubmed: 32447346
Lin H-C, Kuan Y, Chu H-F, Cheng S-C, Pan H-C, Chen W-Y, et al. Disulfiram and 6-Thioguanine synergistically inhibit the enzymatic activities of USP2 and USP21. Int J Biol Macromol. 2021;176:490–7.
pubmed: 33582217
Pan Y, An N, Deng X, Zhang Q, Du X. RNF220 promotes the proliferation of leukaemic cells and reduces the degradation of the cyclin D1 protein through USP22. Blood Cells Molecules Dis. 2021;86:102490.
D’arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011;17(12):1636–40.
pubmed: 22057347
Zhou W, Xu S, Deng T, Zhou R, Wang C. LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A. Hum Cell. 2022;35(1):360–78.
pubmed: 34694569
Niederkorn M, Ishikawa C, Hueneman M, Bartram K, Stepanchick J, Bennett ER. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. 2022;36(2):438–51.
pubmed: 34465865
Ohol YM, Sun MT, Cutler G, Leger PR, Hu DX, Biannic B, et al. Novel, selective inhibitors of USP7 uncover multiple mechanisms of antitumor activity in vitro and in vivo. Mol Cancer Ther. 2020;19(10):1970–80.
pubmed: 32788207
Chae Y-C, Jung H, Kim J-Y, Lee DH, Seo S-B. Ubiquitin-specific peptidase 3 induces TPA-mediated leukemia cell differentiation via regulating H2AK119ub. Anim Cells Syst. 2019;23(5):311–7.
Arimoto K-i, Miyauchi S, Troutman TD, Zhang Y, Liu M, Stoner SA, et al. Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis. Nat Commun. 2023;14(1):251.
pubmed: 36646704
pmcid: 9842760
Yang W, Shih H. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability. Oncogene. 2013;32(43):5167–75.
pubmed: 23208507
Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, et al. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Res. 2010;70(23):9875–85.
pubmed: 20935222
pmcid: 2999664
Li L, Wang Y, Zhang X, Song G, Guo Q, Zhang Z, et al. Deubiquitinase USP48 promotes ATRA-induced granulocytic differentiation of acute promyelocytic leukemia cells. Int J Oncol. 2018;53(2):895–903.
pubmed: 29901102
Liu C, Yao X, Li M, Xi Y, Zhao L. USP39 regulates the cell cycle, survival, and growth of human leukemia cells. Biosci Rep. 2019;39(4):BSR20190040.
pubmed: 30898977
pmcid: 6449567
Sivachandran N, Cao JY, Frappier L. Epstein-Barr virus nuclear antigen 1 hijacks the host kinase CK2 to disrupt PML nuclear bodies. J Virol. 2010;84(21):11113–23.
pubmed: 20719947
pmcid: 2953151
Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network. Nature. 2008;455(7214):813–7.
pubmed: 18716620
pmcid: 3398484
Noguera N, Song M, Divona M, Catalano G, Calvo K, Garcia F, et al. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia. 2013;27(5):1037–43.
pubmed: 23183427
Sarma SN, Kim Y-J, Ryu J-C. Gene expression profiles of human promyelocytic leukemia cell lines exposed to volatile organic compounds. Toxicology. 2010;271(3):122–30.
pubmed: 20359517
Antonenko S, Telegeev G. Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of bcr-abl level in K562 cells. Exp Oncol. 2020;42(2):109–14.
pubmed: 32602291
Liao Y, Liu N, Xia X, Guo Z, Li Y, Jiang L, et al. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. Cell Discovery. 2019;5(1):24.
pubmed: 31044085
pmcid: 6488640
Shibata N, Ohoka N, Tsuji G, Demizu Y, Miyawaza K, Ui-Tei K, et al. Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells. Oncogene. 2020;39(19):3867–78.
pubmed: 32203161
Zhuang H, Ren Y, Mao C, Zhong Y, Zhang Z, Cao B et al. Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemia. J Biol Chem. 2022;298(9).
Antonenko S, Gurianov D, Telegeev G. Colocalization of USP1 and РН domain of bcr-abl oncoprotein in terms of chronic myeloid leukemia cell rearrangements. Cytol Genet. 2016;50:352–6.
Jiang S, Wang X, He Y, Huang H, Cao B, Zhang Z, et al. Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis. Cell Death Dis. 2021;12(5):456.
pubmed: 33963175
pmcid: 8105359
Lei H, Xu H-Z, Shan H-Z, Liu M, Lu Y, Fang Z-X, et al. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia. Nat Commun. 2021;12(1):51.
pubmed: 33397955
pmcid: 7782553
Yan M, Luo J-K, Ritchie KJ, Sakai I, Takeuchi K, Ren R, et al. Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood J Am Soc Hematol. 2007;110(1):305–12.
van den Berk P, Lancini C, Serresi M, Sanchez-Bailon MP, Hulsman D, Pritchard C et al. USP15 deubiquitinase safeguards hematopoiesis and genome integrity in hematopoietic stem cells and leukemia cells. Cell Rep. 2020;33(13).
Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, et al. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013;12(12):2651–62.
pubmed: 24130053
pmcid: 4089878
Morotti A, Panuzzo C, Crivellaro S, Carrà G, Guerrasio A, Saglio G. HAUSP compartmentalization in chronic myeloid leukemia. Eur J Haematol. 2015;94(4):318–21.
pubmed: 25082234
Morotti A, Panuzzo C, Crivellaro S, Pergolizzi B, Familiari U, Berger A, et al. BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. Leukemia. 2014;28(6):1326–33.
pubmed: 24317448
Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, et al. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. J Hematol Oncol. 2016;9(1):1–16.
Chen X, Chen Y, Zhang M, Cheng H, Mai H, Yi M, et al. HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p/USP6/GLS1 axis. Cell Death Dis. 2022;13(1):92.
pubmed: 35091542
pmcid: 8799639
Nie Z-Y, Yao M, Yang Z, Yang L, Liu X-J, Yu J, et al. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance. J Experimental Clin Cancer Res. 2020;39:1–14.
Carrà G, Panuzzo C, Crivellaro S, Morena D, Taulli R, Guerrasio A, et al. The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia. Oncol Lett. 2016;12(5):3123–6.
pubmed: 27899971
pmcid: 5103907
Peiris MN, Meyer AN, Warda D, Campos AR, Donoghue DJ. Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation. Oncotarget. 2022;13:659.
pubmed: 35574218
pmcid: 9093983
Zhou Y, Han C, Wang E, Lorch AH, Serafin V, Cho B-K, et al. Posttranslational regulation of the exon skipping machinery controls aberrant splicing in leukemia. Cancer Discov. 2020;10(9):1388–409.
pubmed: 32444465
pmcid: 7483384
Niederkorn M, Hueneman K, Choi K, Varney ME, Romano L, Pujato MA, et al. TIFAB regulates USP15-mediated p53 signaling during stressed and malignant hematopoiesis. Cell Rep. 2020;30(8):2776–90. e6.
pubmed: 32101751
pmcid: 7384867
Kuang X, Xiong J, Lu T, Wang W, Zhang Z, Wang J. Inhibition of USP1 induces apoptosis via ID1/AKT pathway in B-cell acute lymphoblastic leukemia cells. Int J Med Sci. 2021;18(1):245.
pubmed: 33390793
pmcid: 7738972
Gong H, Liu L, Cui L, Ma H, Shen L. ALKBH5-mediated m6A‐demethylation of USP1 regulated T‐cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B. Mol Carcinog. 2021;60(9):644–57.
pubmed: 34169564
Jin Q, Gutierrez Diaz B, Pieters T, Zhou Y, Narang S, Fijalkwoski I, et al. Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia. Sci Adv. 2022;8(49):eabq8437.
pubmed: 36490346
pmcid: 9733937
Shaw TI, Dong L, Tian L, Qian C, Liu Y, Ju B, et al. Integrative network analysis reveals USP7 haploinsufficiency inhibits E-protein activity in pediatric T-lineage acute lymphoblastic leukemia (T-ALL). Sci Rep. 2021;11(1):5154.
pubmed: 33664368
pmcid: 7933146
Shan H, Li X, Xiao X, Dai Y, Huang J, Song J, et al. USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia. Signal Transduct Target Therapy. 2018;3(1):29.
Jin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutierrez-Diaz BT, Wang KK, et al. USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T-cell leukemia. Clin Cancer Res. 2019;25(1):222–39.
pubmed: 30224337
Yasunaga J, Lin FC, Lu X, Jeang K-T. Ubiquitin-specific peptidase 20 targets TRAF6 and human T cell leukemia virus type 1 tax to negatively regulate NF-κB signaling. J Virol. 2011;85(13):6212–9.
pubmed: 21525354
pmcid: 3126525
Trivigno D, Essmann F, Huber SM, Rudner J. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia. 2012;14(10):893–IN4.
pubmed: 23097624
pmcid: 3479835
Luo H, Jing B, Xia Y, Zhang Y, Hu M, Cai H, et al. WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia. Cancer Cell Int. 2019;19(1):1–14.
Takahashi M, Higuchi M, Makokha GN, Matsuki H, Yoshita M, Tanaka Y, et al. HTLV-1 tax oncoprotein stimulates ROS production and apoptosis in T cells by interacting with USP10. Blood. J Am Soc Hematol. 2013;122(5):715–25.
Chuang S-J, Cheng S-C, Tang H-C, Sun C-Y, Chou C-Y. 6-Thioguanine is a noncompetitive and slow binding inhibitor of human deubiquitinating protease USP2. Sci Rep. 2018;8(1):3102.
pubmed: 29449607
pmcid: 5814560
Gavory G, O’Dowd CR, Helm MD, Flasz J, Arkoudis E, Dossang A, et al. Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat Chem Biol. 2018;14(2):118–25.
pubmed: 29200206
De Pittà C, Tombolan L, Dell’Orto MC, Accordi B, te Kronnie G, Romualdi C, et al. A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica. 2005;90(7):890–8.
pubmed: 15996926
Zhang Y, van Deursen J, Galardy PJ. Overexpression of ubiquitin specific protease 44 (USP44) induces chromosomal instability and is frequently observed in human T-cell leukemia. PLoS ONE. 2011;6(8):e23389.
pubmed: 21853124
pmcid: 3154946
Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, et al. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. Blood J Am Soc Hematol. 2017;130(2):156–66.
Carrà G, Panuzzo C, Torti D, Parvis G, Crivellaro S, Familiari U, et al. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. Oncotarget. 2017;8(22):35508.
pubmed: 28418900
pmcid: 5482594
Wei Z, Su L, Gao S. The roles of ubiquitination in AML. Ann Hematol. 2023:1–16.
Yuan LL, Green A, David L, Dozier C, Récher C, Didier C, et al. Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia. Leuk Res. 2014;38(11):1342–9.
pubmed: 25281057
Iland HJ. Curative strategies in APL. Semin Hematol. 2019;56(2):131–8.
pubmed: 30926089
Chang HR, Munkhjargal A, Kim M-J, Park SY, Jung E, Ryu J-H, et al. The functional roles of PML nuclear bodies in genome maintenance. Mutat Research/Fundamental Mol Mech Mutagen. 2018;809:99–107.
Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72.
pubmed: 10403855
Parriott G, Kee BL. E protein transcription factors as suppressors of T lymphocyte acute lymphoblastic leukemia. Front Immunol. 2022;13:885144.
pubmed: 35514954
pmcid: 9065262
Dos Santos NR, Ghezzo MN, Da Silva RC, Fernandes MT. NF-κB in T-cell acute lymphoblastic leukemia: oncogenic functions in leukemic and in microenvironmental cells. Cancers. 2010;2(4):1838–60.
pubmed: 24281204
pmcid: 3840450
Rodríguez D, Bretones G, Arango JR, Valdespino V, Campo E, Quesada V, et al. Molecular pathogenesis of CLL and its evolution. Int J Hematol. 2015;101(3):219–28.
pubmed: 25630433
Danilov AV, Danilova OV, Klein AK, Huber BT. Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med. 2006;6(6):665–75.
pubmed: 17022736
Spano D, Catara G. Targeting the ubiquitin–proteasome system and recent advances in Cancer Therapy. Cells. 2023;13(1):29.
pubmed: 38201233
pmcid: 10778545